Essex Bio-Technology Balance Sheet Health
Financial Health criteria checks 6/6
Essex Bio-Technology has a total shareholder equity of HK$1.9B and total debt of HK$271.9M, which brings its debt-to-equity ratio to 14.1%. Its total assets and total liabilities are HK$2.8B and HK$903.8M respectively. Essex Bio-Technology's EBIT is HK$351.6M making its interest coverage ratio -310.8. It has cash and short-term investments of HK$515.0M.
Key information
14.1%
Debt to equity ratio
HK$271.92m
Debt
| Interest coverage ratio | -310.8x |
| Cash | HK$515.03m |
| Equity | HK$1.92b |
| Total liabilities | HK$903.78m |
| Total assets | HK$2.83b |
Recent financial health updates
Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet
Dec 07
Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 07Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?
Jun 22Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Jun 29Is Essex Bio-Technology (HKG:1061) A Risky Investment?
Mar 31Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 13
Recent updates
Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement
May 06Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)
Mar 21Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet
Dec 07Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 07Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04
Aug 25Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?
Jun 22Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055
May 02Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055
Mar 30Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Jun 29Is Essex Bio-Technology (HKG:1061) A Risky Investment?
Mar 31If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today
Mar 13How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?
Feb 15Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?
Jan 25Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Jan 04Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 13Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters
Nov 23Financial Position Analysis
Short Term Liabilities: 1061's short term assets (HK$1.2B) exceed its short term liabilities (HK$810.7M).
Long Term Liabilities: 1061's short term assets (HK$1.2B) exceed its long term liabilities (HK$93.0M).
Debt to Equity History and Analysis
Debt Level: 1061 has more cash than its total debt.
Reducing Debt: 1061's debt to equity ratio has reduced from 20.4% to 14.1% over the past 5 years.
Debt Coverage: 1061's debt is well covered by operating cash flow (124.7%).
Interest Coverage: 1061 earns more interest than it pays, so coverage of interest payments is not a concern.